Cost-Effectiveness and Estimated Health Benefits of Treating Patients with Vitamin D in Pre-Dialysis
- 5 March 2020
- journal article
- research article
- Published by Walter de Gruyter GmbH in Forum for Health Economics and Policy
- Vol. 23 (1)
Abstract
Background: The optimal timing of treatment with vitamin D therapy for patients with chronic kidney disease (CKD), vitamin D insufficiency, and secondary hyperparathyroidism (SHPT) is a pressing question in nephrology with economic and patient outcome implications. Objective: The objective of this study was to estimate the cost-effectiveness of earlier vitamin D treatment in CKD patients not on dialysis with vitamin D insufficiency and SHPT. Design: A cost-effectiveness analysis based on a Markov model of CKD progression was developed from the Medicare perspective. The model follows a hypothetical cohort of 1000 Stage 3 or 4 CKD patients over a 5-year time horizon. The intervention was vitamin D therapy initiated in CKD stages 3 or 4 through CKD stage 5/end-stage renal disease (ESRD) versus initiation in CKD stage 5/ESRD only. The outcomes of interest were cardiovascular (CV) events averted, fractures averted, time in CKD stage 5/ESRD, mortality, quality-adjusted life years (QALYs), and costs associated with clinical events and CKD stage. Results: Vitamin D treatment in CKD stages 3 and 4 was a dominant strategy when compared to waiting to treat until CKD stage 5/ESRD. Total cost savings associated with treatment during CKD stages 3 and 4, compared to waiting until CKD stage 5/ESRD, was estimated to be $19.9 million. The model estimated that early treatment results in 159 averted CV events, 5 averted fractures, 269 fewer patient-years in CKD stage 5, 41 fewer deaths, and 191 additional QALYs. Conclusions: Initiating vitamin D therapy in CKD stages 3 or 4 appears to be cost-effective, largely driven by the annual costs of care by CKD stage, CV event costs, and risks of hypercalcemia. Further research demonstrating causal relationships between vitamin D therapy and patient outcomes is needed to inform decision making regarding vitamin D therapy timing.Keywords
This publication has 37 references indexed in Scilit:
- Vitamin D supplementation and mortality risk in chronic kidney disease: a meta-analysis of 20 observational studiesBMC Nephrology, 2013
- Baseline characteristics of patients with chronic kidney disease stage 3 and stage 4 in spain: the MERENA observational cohort studyBMC Nephrology, 2011
- Vitamin D Supplementation in Chronic Kidney DiseaseClinical Journal of the American Society of Nephrology, 2011
- Chronic Kidney Disease and the Risk of End-Stage Renal Disease versus DeathJournal of General Internal Medicine, 2010
- Vitamin D compounds for people with chronic kidney disease requiring dialysisCochrane Database of Systematic Reviews, 2009
- Vitamin D Affects Survival Independently of Vascular Calcification in Chronic Kidney DiseaseClinical Journal of the American Society of Nephrology, 2009
- Serum 25-hydroxyvitamin D as an independent determinant of 1-84 PTH and bone mineral density in non-diabetic predialysis CKD patientsBone, 2009
- 25-Hydroxyvitamin D Deficiency and Diabetes Predict Reduced BMD in Patients With Chronic Kidney DiseaseJournal of Bone and Mineral Research, 2006
- Predictive cardiovascular risk factors in patients with chronic kidney disease (CKD)Kidney International, 2005
- Chronic Kidney Disease and the Risks of Death, Cardiovascular Events, and HospitalizationNew England Journal of Medicine, 2004